ABSTRACT
Background: Single-isocenter (SI) noncoplanar volumetric modulated arc therapy (NC-VMAT) has been widely used in stereotactic radiosurgery (SRS) or hypofractionated stereotactic radiotherapy (HSRT) for multiple brain metastases (BMs). However, it is critical to verify patient positioning at a noncoplanar couch angle. This study aimed to compare the noncoplanar setup discrepancies between kilo-voltage/mega-voltage image (kV/MV) orthogonal image pairs with a 2-dimensional/3-dimensional (2D/3D) matching mode and noncoplanar cone-beam computed tomography (NC-CBCT) with a 3D/3D matching mode in SI NC-VMAT HSRT for multiple BMs. Methods: Twenty patients with multiple BMs [2-5] who underwent SI NC-VMAT HSRT were enrolled in this study. Prior to each noncoplanar field delivery, both kV/MV orthogonal image pairs and NC-CBCT were used to determine setup errors. The setup error values reported by NC-CBCT were defined as the gold standard and compared to those reported by kV/MV orthogonal image pairs. The Bland-Altman analysis method was utilized to assess the agreement of the two positioning modalities. Results: In total, 104 kV/MV image pairs and NC-CBCT scans were acquired. The mean setup error differences (SEDs; absolute values) between the two positioning systems were 0.17 mm, 0.21 mm, 0.16 mm, 0.22°, 0.18°, and 0.17° in the vertical, longitudinal, lateral, yaw, pitch, and roll directions, respectively. The maximum SEDs regarding translation and rotation occurred in the longitudinal and yaw directions at 0.60 mm and 0.8°, respectively. Bland-Altman analysis showed excellent agreement between the two positioning modalities, and the 95% limits of agreement (LOAs) never exceeded 0.6 mm and 0.6° in the translational and rotational directions, respectively. Only 4.80% of SEDs exceeded the tolerance of 0.5 mm/0.5°. Conclusions: Orthogonal kV/MV image pairs with 2D/3D matching mode could provide comparable accuracy for noncoplanar positioning as NC-CBCT with 3D/3D matching mode.
ABSTRACT
Background: Lung cancer is the second most common form of malignant tumor and has the highest mortality rate worldwide. Among its subtypes, lung adenocarcinoma is the most prevalent. Leptomeningeal metastasis (LM) is rare and is characterized by a dismal prognosis, with overall survival periods typically spanning 4 to 6 weeks without treatment. However, in specific cases, survival can be extended to 4 to 6 months with appropriate therapy. The recent approval of third-generation tyrosine kinase inhibitors (TKIs), such as osimertinib, aumolertinib, and furmonertinib, has introduced promising treatment options for individuals with non-small cell lung cancer (NSCLC) who develop LM after developing resistance to first- and second-generation TKIs. These third-generation TKIs exhibit an enhanced ability to penetrate the blood-brain barrier (BBB), opening up new avenues for managing this challenging condition. Case summary: We report the case of a 48-year-old Chinese man diagnosed with advanced NSCLC harboring an epidermal growth factor receptor (EGFR) mutation. Following a pulmonary lobectomy and postoperative adjuvant therapy with gefitinib, the patient was diagnosed with LM, which was confirmed by his neurologic symptoms, cerebrospinal fluid cytologic analysis, and cranial enhancement magnetic resonance imaging. Subsequently, he received oral treatment in the form of 160 mg of furmonertinib daily. After 5 days of furmonertinib therapy, the patient recovered from lethargy, with an obvious improvement in cognitive function. Follow-up visits revealed a 6-month survival period following the LM diagnosis. Patients with NSCLC and LM typically present with severe symptoms, and the efficacy of systemic treatment, intrathecal chemotherapy, and radiotherapy remains unsatisfactory. We hope that this specific case provide valuable insights into the management of patients with EGFR mutation-associated NSCLC with LM. Conclusion: Furmonertinib, a third-generation EGFR TKI with notable BBB penetration, shows promise in LM control and the rapid alleviation of intracranial symptoms. Further investigations into appropriate dosage and toxicity management are imperative.
